BMPR2 and pulmonary arterial hypertension: Combination therapy of AAV1.SERCA2a with AAV1.BMPR2 and STAT3 inhibitors in a severe model of PAH: Combination therapy is now considered the standard of care in PAH to target multiple pathogenic pathways [30,31,32].